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Cardiac and smooth muscleInvestigations undertaken over the past years have led scientists to introduce the concept of protein
quality control (PQC) systems, which are responsible for polypeptide processing. The PQC system
monitors proteostasis and involves activity of different chaperones such as small heat shock pro-
teins (sHSPs). These proteins act during normal conditions as housekeeping proteins regulating cel-
lular processes, and during stress conditions. They also mediate the removal of toxic misfolded
polypeptides and thereby prevent development of pathogenic states. It is postulated that sHSPs
are involved in muscle development. They could act via modulation of myogenesis or by mainte-
nance of the structural integrity of signaling complexes. Moreover, mutations in genes coding for
sHSPs lead to pathological states affecting muscular tissue functioning.
This review focuses on the question how sHSPs, still relatively poorly understood proteins,
contribute to the development and function of three types of muscle tissue: skeletal, cardiac and
smooth.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Organisms, to reduce their susceptibility to various environ-
mental and cellular stresses, have developed so-called protein
quality control (PQC) systems, in which all members of the small
heat shock protein (sHSP) family take part. sHSPs are the ﬁrst line
of defense against misfolded polypeptides with a tendency to
aggregation. Abnormalities in this defense mechanism caused,
e.g. by mutations in genes encoding its components, may lead to
disruption of protein folding, structure and function, and can result
in diseases such as skeletal and cardiac myopathies and neurolog-
ical disorders [for review see [1]].
sHSPs (HSPBs) [2] are described as molecular chaperones
involved in the response to stress conditions such as heat or
oxidative stress [3]. The activity of sHSPs does not require ATP,
and unlike some other heat shock proteins they are unable to
refold damaged proteins. Their main task is maintaining the
soluble state of unfolded proteins and preventing their precipita-
tion [3] (Fig. 1). Representatives of this family are known from
all domains: Archaea [4], bacteria [5], and eukaryotes, including
fungi [6], plants [7] and animals [8]. Most of the organisms haveseveral different homologues of sHSPs: a few in bacteria and
yeast [6], 10 in humans [9], 13 in zebraﬁsh [10], and up to 15
in plants [11]. In higher eukaryotes the distribution of each sHSP
is subcellular and/or tissue speciﬁc [12,13]. Mutations in
sHSPs are connected with some severe pathologies such as
desmin-related myopathy, distal hereditary motor neuropathy,
Charcot–Marie–Tooth (CMT) disease, cataract and neurodegener-
ative diseases [14].
1.1. Structure and activity of sHSPs
The mass of a single sHSP molecule varies between 15 and
40 kDa. Each sHSP contains a highly conserved 80–100 amino acid
a-crystalline domain (ACD), essential for its activity. There are a
few atomic resolution structures obtained from whole molecules
– the archeon Methanococcus jannaschii [4], wheat Triticum aes-
tivum [7] and tape worm Taenia saginata [8] – and some from ver-
sions shortened on both ends containing an ACD core [15]. The ACD
forms an immunoglobulin-like b sandwich fold composed of nine b
strands. Two b sheets of the b sandwich are composed of respec-
tively four (b2, b3, b8, b9) and three (b4, b5, b7) b strands. The core
a-crystalline domain is ﬂanked with longer N-terminal and shorter
C-terminal regions, variable in length and amino acid composition
[16]. Interactions between pockets formed in the a-crystalline
Fig. 1. Involvement of sHSPs in maintenance of cellular protein homeostasis. The main task of sHSPs is maintaining the soluble state of unfolded proteins and preventing their
precipitation and formation of potentially toxic aggregates. They are part of the multicomponent machinery responsible for monitoring all steps of the protein life cycle which
comprises inter alia synthesis, folding, aggregation, refolding and degradation. sHSPs participate, together with the Hsp70/Hsp40 machinery, in restoration of native
conformation of unfolded or partially folded polypeptides, or in their proteasomal degradation when the repair of damage is impossible. Due to interactions with different
partners some sHSPs direct proteins to alternative degradation pathways such as CASA (chaperone-assisted selective autophagy). See main text for a detailed description.
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of sHSP and in the formation of clusters [17,18].
In the inactive state most sHSPs form large oligomers, assem-
bled from both homo- and heterodimers [19]. Monomers within
a dimer are connected in an antiparallel manner, by reciprocal ﬁt-
ting of a b6 strand into the neighboring protein molecule or by
interactions between elongated b6/b7 strands [18]. The C-terminal
region is rather involved in dimer formation, whereas the N-termi-
nal region is found to stabilize highly organized oligomers [16,17].
The C-terminal end contains a conservative I/V/L-X-I/V/L sequence
which is reported to ﬁt inside the b4/b8 groove [20] and is respon-
sible for the intrinsically disordered state of this part of the protein.
Since forms of sHSPs truncated on the C-termini are connected
with cataract, the accessibility of the b4/b8 groove affected by a
ﬂexible C-terminus may be signiﬁcant in regulation of chaperone
activity [18,21]. Dissociation of both monomers and dimers from
the oligomers is required for sHSP activity, and is regulated by
phosphorylation of multiple sites in the N-termini [22,23]. Addi-
tionally, the dimeric state enables creation of a hydrophobic groove
between monomers, essential for binding unfolded peptides [24].
Distortions and charge shifts present in many mutated forms of
sHSPs slightly alter the interfaces inside the dimer and cause clo-
sure of the groove [24].
The most prominent activity of sHSPs is binding proteins and
protecting them from aggregation. Antiaggregation properties of
sHSPs may inhibit aggregation of many pathogenic proteins which
cause various neurodegenerative diseases, such as Parkinson’s dis-
ease (PD), Alzheimer’s disease (AD), dementia with Lewy bodies or
Huntington’s disease (HD). Formation of ﬁlaments by both wild-
type and mutated (PD) forms of alpha-synuclein can be stopped
in the presence of sHSPs, especially HSPB8 [25]. There are also re-
ports suggesting that some sHSPs enhance dissolving of senile pla-
ques present in AD [26,27] and suppress aggregation of
polyglutamate proteins by interacting with their Josephin domain,
which is responsible for the initial steps of aggregation of polyQ
proteins [28]. It is suggested that some of these effects can becaused by promoting autophagy and/or an inﬂammatory response
after detection of misfolded proteins by sHSPs [29–31].
sHSPs are able to bind most unfolded proteins in a non-speciﬁc
manner, preventing their aggregation; however, there are also
more regular partners and a pin array assay indicated speciﬁc bind-
ing sites for different proteins. HSPB5 (a.k.a aB-crystallin) has,
aside from chaperone sites, the ability to bind intermediate ﬁla-
ments (desmin, GFAP), actin microﬁlaments and some growth fac-
tors [32–34]. Also HSPB8 is noted to interact with partner protein
Bag3 [35], which connects sHSP with Hsc70, directing proteins to
refolding, and to autophagy or proteasomal degradation
[29,30,36,37].
1.2. Interaction of sHSPs with cytoskeletal elements and other binding
partners
Many representatives of the sHSP family – HSPB1 (a.k.a HSP27),
HSPB4, HSPB5 and HSPB6 – have been studied in the context of
their cytoskeleton interactions. Their interactions with the cyto-
skeleton and abilities to affect its structure and dynamics are
mainly described at the level of microﬁlaments and intermediate
ﬁlaments (IFs) [34,38–41]. Different sHSPs were noted to colocalize
with various IFs such as keratin 18, GFAP or desmin [34]. All men-
tioned sHSPs stabilize and modulate monomer assembly/disas-
sembly of the ﬁlaments. The character of this activity is closely
connected with the phosphorylated/unphosphorylated state of
sHSPs. For example, unphosphorylated HSPB1, in its large oligo-
meric state, is able to bind up to 30 actin monomers, whereas its
phosphorylation leads to disintegration of the large complex [42].
Since HSPB5 can inhibit both aggregation and assembly of desmin,
mutations in its crystalline domain that increase afﬁnity toward IF
cause aberrant desmin aggregation [43,44]. A similar mechanism
can also lead to formation of vimentin aggregates in cataract orig-
inating from HSPB5 mutation [45]. Additionally, CMT disease phe-
notype caused by HSPB1 (S135F) mutation also corresponds to
abnormal microtubule stabilization due to higher afﬁnity of the
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hand, HSPB1 in the unphosphorylated, monomeric state inhibits
polymerization of actin microﬁlaments by capping their plus end
[47], whereas phosphorylated forms are involved in ﬁlament
dynamics and protect the cell from defective actin aggregates
[48,49].
Most sHSPs also show antiapoptotic properties and are overex-
pressed in various types of cancer [50,51]. Aside from binding mis-
folded proteins and intermediate apoptosis prevention, some
sHSPs can also directly interact with proapoptotic and antiapopto-
tic proteins, through speciﬁc pathways and active sites which dif-
fer among sHSPs.
HSPB1 appears to have a major role in apoptosis regulation.
This protein is able to prevent apoptosis caused by heat shock,
oxidative stress, ischemia or apoptosis effectors. HSPB1 stops re-
lease of Smac (small mitochondria-derived activator of caspases)
to the cytoplasm, and binds already released cytochrome-c and
caspase 3 [52,53]. It was also reported to indirectly inhibit
translocation of Bax into the mitochondria, through PI-3 kinase
activation which activates prosurvival kinase Akt and promotes
its interaction with Bax [54]. HSPB1 is also implicated in in-
creased phosphorylation and cytoplasmic localization of cyclin-
dependent kinase inhibitor p21, promoting cell survival and cell
cycle progression. In contrast, inactivation of HSPB1 prevents
p21 translocation, stops the cell cycle and enhances cell death
[55,56]. Another antiapoptotic pathway consists in the protec-
tion of eIF4E (eukaryotic translational initiation factor 4E) from
its ubiquitin–proteasome degradation [57,58]. In the caspase-
independent apoptosis pathway, HSPB1 prevents binding of
Daxx (death domain-associated protein 6) with Ask1 (apoptosis
signal regulated kinase 1) and Fas (regulator of cell death), and
inhibits their proapoptotic activities [59]. HSPB1 also contributes
to resistance to doxorubicin and other anticancer drugs [55].
Additionally, HSPB1 oligomer size, phosphorylated sites and sub-
cellular localization differ depending on the character of apopto-
tic effectors. Etoposide and Fas antibody presence results in
accumulation of medium and large oligomers, while stauro-
sporine and cytochalasin B induce a small oligomer state [60].
HSPB1 has also neuroprotective properties derived from reduc-
ing the toxic effect of mutated SOD1 in ALS (amyotrophic lateral
sclerosis) disorder [61,62].
The antiapoptotic function of HSPB5 was shown to involve inhi-
bition of the RAS-initiated RAF/MEK/ERK signaling pathway. Stud-
ies on rabbit lens epithelial cells revealed that HSPB5
overexpression decreases the apoptosis rate by preventing RAS
activation [63]. Downstream HSPB5 is able to stop Bax and Bcl-2
translocation from cytoplasm to mitochondria, as demonstrated
in retinal pigment cells [64]. A similar effect was observed in myo-
blast cultures treated with hydrogen peroxide, where HSPB5 inter-
acted with p53 to retain it in the cytoplasm [65]. Additionally,
HSPB5 inhibits autocatalytic maturation of caspase-3 [66]. More
recent studies supported this ﬁnding in vivo, showing antiapoptotic
properties of HSPB5 in stressed retinal pigment epithelial cells
[67].
HSPB8 is associated with cell proliferation and protection from
apoptosis in melanoma, glioblastoma and breast cancer cells [68–
70]. Depending on the cancer type the mechanisms of HSPB8 anti-
apoptotic activity may differ. In melanocytes overexpression of
HSPB8 enhances tumor transformation during the G1 cell cycle
stage. On the other hand, in glioblastoma cells HSPB8 opposes
Sam68, and facilitates cell cycle progression from G1 to S by en-
hanced expression of cell cycle regulatory proteins such as cyclins
E and A or PCNA [69]. HSPB8 is also able to activate the PI3K/Akt
pathway in cardiac cells, and supports their growth and survival
[71]. Yet in some other tumor tissues the level of HSPB8 is lowerthan in normal cells, and restoring normal concentrations by both
DNA demethylation and cell transfection results in apoptosis
induced in two independent pathways: caspase- and p38MAPK-
dependent [72]. Thus the role of HSPB8 cannot be simply described
as pro- or antiapoptotic. It is notable that the dual nature of this
protein is not an exception among sHSP family members.
2. Involvement of sHSPs in skeletal muscle
2.1. Myogenesis
Skeletal muscle myogenesis is a developmental cascade orches-
trated by many various intrinsic and extrinsic factors. During the
early steps of myogenesis mononucleated myogenic cells divide
mitotically; they then withdraw from the cell cycle to become
myoblasts, and later fuse into multinucleate myotubes that differ-
entiate into adult muscle ﬁbers [73].
Thekey step for the entryof progenitormuscle cells into themyo-
genic program is the induction (by signals emanating from nearby
tissues, suchasneural tube, thenotochord, and thedorsal and lateral
ectoderm) of myogenic bHLH (basic/Helix-Loop-Helix) myogenic
regulatory factors (MRFs). The regulatory gene family involved in-
cludesMyoD [74],Myf-5 [75],myogenin [76] andMRF-4 [77]. MyoD
andMyf-5are responsible for determinationofmyogenicprecursors
whereas myogenin and MRF-4 play the crucial role in terminal dif-
ferentiation of muscle ﬁbers [78]. Besides the MyoD family of myo-
genic transcription factors, members of the MEF2 (Myocyte
Enhancer Factor 2) family of transcription factors play an important
role in muscle gene activation. MEF2 proteins are MADS-box-con-
taining transcription factors that bind as homo- or heterodimers to
a conserved A/T rich DNA sequence (MEF2 site) present in the regu-
latory regions of many muscle-speciﬁc genes [79]. MEF2 and bHLH
myogenic transcription factors cooperate synergistically to stimu-
late muscle-speciﬁc genes containing both E-boxes and MEF2 sites
[for review see: [80]].
An important aspect of muscle differentiation is generation of
multinucleated muscle ﬁbers through fusion of mononucleated
myoblasts. Several studies have shown that sHSPs are expressed
during the key steps of muscle differentiation. Many researchers
have turned to mouse C2C12 myoblasts, used as a model for
myogenesis, to elucidate the role of sHSPs during muscle differ-
entiation. It has been reported that an MRF-binding site exists
in the gene (CRYAB)encoding HSPB5. It was also shown that in
C2C12 myoblasts MyoD and myogenin can activate the HSPB5
enhancer in muscle by interaction with the MRF site [81]. The
studies conducted by Ito et al. [82] revealed accumulation of
HSPB1 and HSPB5 during differentiation of C2C12 cells into myo-
tubes, a process regulated by protein kinase cascades. During
C2C12 differentiation HSPB5 modulates MyoD activity by reduc-
tion of its synthesis and increasing its degradation, thus leading
to delayed muscle differentiation [83]. In vivo studies demon-
strated that during mouse myogenesis HSPB5 mRNA shows early
expression in myotomes and developing skeletal muscles [84].
These data strongly suggest an important role of HSPB5 for prop-
er myogenesis. It was also revealed that HSPB1 is a target gene
for transcription of MEF2 factors regulating advanced stages of
myogenesis [85]. The authors assume that MEF2 factors, in con-
junction with MyoD and other myogenic regulatory factors,
may be involved in up-regulation of HSPB1 in differentiated skel-
etal muscles. Studies carried out by Sugiyama et al. [86] have
demonstrated that skeletal muscle develops two chaperone sys-
tems which work independently in muscle maintenance and dif-
ferentiation. One system includes HSPB2 and HSPB3, and the
other HSPB5, HSPB1 and HSPB6. The expressions of HSPB2 and
HSPB3 was observed during muscle differentiation under control
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tightly regulated by a myogenic program, closely related to mus-
cle differentiation. HSPB1 and HSPB5 make a myotube-speciﬁc
association with actin microﬁlaments, which conﬁrms their cyto-
protective role [86]. It is also worth noting that in myoblasts
HSPB1 was not observed, suggesting the possible involvement
of these sHSPs in initial organization of myoﬁbril assembly in
myotubes. In mature muscles HSPB2 did not show a similar
localization on actin bundles, although it localized on the Z-line
similarly to HSPB5. In adult skeletal muscles HSPB5 was ex-
pressed in slow and fast muscles and localized in Z-bands [87].
The involvement of sHSPs in myogenesis (as well as in cardio-
genesis, see Section 3.1: ‘‘Cardiogenesis’’) was also investigated in
another model organism – Danio rerio (zebraﬁsh) using ‘‘knock-
down’’ of HSPB1 with morpholino antisense oligonucleotides in
developing zebraﬁsh embryos. Initially it was thought that in zeb-
raﬁsh depletion of this protein does not have an effect on skeletal
or cardiac muscle morphology and functioning [88]. However, de-
tailed analysis of morphants revealed that HSPB1 takes part in reg-
ulation of craniofacial muscle development [89]. Its depletion
inﬂuences optimal growth of craniofacial myocytes rather than
determination or proliferation of myogenic precursors. This obser-
vation suggests that zebraﬁsh HSPB1 may not be involved in mor-
phogenesis of skeletal and cardiac muscles or in myoﬁlament
organization, and its physiological role could be rather connected
with protection of myocytes against mechanical or oxidative stress
[90]. Similar results were obtained for a mouse model in which
suppression of HSPB1 expression also did not cause phenotype
changes [85]. This phenomenon was explained by a compensation
effect which may be elicited by other sHSPs expressed in cardiac
and skeletal muscle, e.g. HSPB2, HSPB5 and HSPB8. To examine this
assumption double knockout experiments were undertaken. For
example, in Hspb5/Hspb2 knockout mice Brady et al. [91] observed
severe muscle cell abnormalities. Loss of HSPB5 and HSPB2 func-
tions leads to degeneration of some skeletal muscles, especially
tongue and soleus muscles [91]. These ﬁndings suggest that sHSPs
may be speciﬁc myoﬁbril-stabilizing proteins. In the case of cardi-
ogenesis, experiments carried out on double knockout mouse for
Hspb2 and Hspb5 suggested that these protein are dispensable for
the development of mouse myocardium [91,92].
2.2. Multiple functions of sHSPs in muscles
Skeletal muscle is a multinucleated, highly specialized tissue
made up of over ten thousand different kinds of proteins. The dom-
inant proteins of muscle ﬁber sarcoplasm are actin and myosin.
Contractile proteins present in the myoﬁbers are highly organized
in a repetitive manner and assembled into sarcomeric units. Due to
this contractile units muscles are able to accomplish their main
task, which is putting the body in motion. On the other hand, sar-
comeres are exposed to mechanical and metabolic damage. To
minimize undesirable side effects in the form of protein degrada-
tion and/or accumulation of unfolded or toxic polypeptides, organ-
isms have developed an evolutionarily conserved protection
mechanism which is part of the PQC system [93]. Members of this
system – sHSPs – have been shown to be of central importance in
skeletal muscle development and differentiation, and are of poten-
tial signiﬁcance in human diseases. Many different lines of evi-
dence suggest that sHSPs are highly expressed in skeletal
muscles and protect them from heat and from oxidative and
mechanical stresses, particularly during exercise [94–96].
Seven members of the small heat shock proteins can be found in
skeletal muscle: HSPB1, HSPB2, HSPB3, HSPB5, HSPB6, HSPB7 and
HSPB8. To determine whether sHSPs protect skeletal muscle cells
against oxidative stress, Escobedo et al. [96] used two models: dif-
ferentiation-induced increases in HSPB1 and overexpression ofHSBP1 in stably transfected myoblasts. The authors showed that
HSPB1 protects skeletal muscle cells from reactive oxygen species
(ROS)-induced damage by increasing the glutathione (GSH) level. It
has been shown that an increased level of HSPB1 is associated with
an increased level of GSH and decreased hydrogen peroxide-med-
iated cell damage as well as protein oxidation. These ﬁndings indi-
cate that HSPB1 protects skeletal myoblasts against oxidative
stress and may play a key role in regulating the GSH system and
resistance to ROS in skeletal muscle cells.
It has been demonstrated that exposure of samples of rat dia-
phragm to heat stress results in the redistribution of HSPB6, HSPB5
and HSPB1 from the cytoplasm to insoluble fractions (a character-
istic response of sHSPs to heat stress) [94]. In C2C12 undifferenti-
ated mouse myoblasts and differentiated myotubes upon heat
stress, HSPB5 and HSPB1 translocate from the cytoplasm into the
nucleus and colocalize signiﬁcantly with the intranuclear lamin
A/C speckles in myoblasts. The authors believe that sHSPs may play
a crucial role in formation and/or stabilization of the dynamics of
lamin A/C architecture. Interestingly, this translocation of HSPB5
and HSPB1 into the nucleus appears to be differentiation stage-
speciﬁc, implying its functional signiﬁcance [97].
The engagement of sHSPs in stabilization of sarcomeric units
was also investigated in an invertebrate (Drosophila melanogaster).
During muscle contraction some proteins such as ﬁlamin undergo
reversible unfolding and refolding. These periodic conformational
changes make it susceptible to malfunction, which in consequence
may lead to formation of toxic aggregates and disruption of
myoﬁbrillar structure. To prevent unfavorable accumulation,
stress-exposed protein is coupled with a complex formed by, inter
alia, co-chaperone BAG3 (Starvin in D. melanogaster), chaperone
Hsc70 and HSPB8 (Dm-HSP67Bc in D. melanogaster) and HSPB6
[98]. Members of the complex mentioned above (e.g. HSPB8)
localize in the Z band in muscle tissue, which implies their
involvement in Z disk maintenance [98,99].
As stated above, sHSPs have a general function in skeletal mus-
cles. Many different lines of evidence indicate that mutations in
genes encoding sHSPs are linked to several inherited muscle de-
fects. Numerous pathologic states of muscles are caused by muta-
tions of the CRYAB gene. HSPB5 in normal conditions serves the
role of chaperone protein in muscles, stabilizing desmin ﬁlaments,
preventing their aggregation and protecting them from tension-re-
lated damage. Mutations of CRYAB genes lead to a series of muscle
pathologies including one third of cases of desmin-related myopa-
thy (DRM) (see Section 5: ‘‘Pathological aspects of sHSPs’’).
2.3. sHSPs protect muscles during exercise
A body of evidence has revealed that sHSPs play an important
role as cytoskeleton-protective proteins under eccentric exercise
(contraction with active muscle lengthening). Studies of Paulsen’s
group [100] showed that a single bout of unaccustomed maximal
eccentric exercise stimulates acute HSPB1 and HSPB5 translocation
to myoﬁbrillar structures during exercise, with a subsequent in-
crease in mRNA and protein levels for HSPB1 and HSPB5. Of inter-
est, muscle lengthening contractions lead to loss of Z-disk and
membrane scaffolding proteins and concomitant translocation of
HSPB1 and HSPB5 to the Z-disk. Lengthening contraction-induced
translocation of HSPB1 and HSPB5 was associated with phosphor-
ylation of these sHSPs, which may promote their protective activ-
ity. This observation conﬁrms that sHSPs may help to stabilize
skeletal muscle cells and limit their cytoskeletal disruption in mus-
cle cells through the repair of structures damaged during exercise,
which may also generate ROS that can unfavorably affect cellular
components [101].
During intensive muscle activity such as exercise, muscle ﬁber
injury may occur as a consequence of the signiﬁcant increase in
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rillogenesis and maintenance of cytoskeletal organization in condi-
tions of hyperthermia have also been postulated. For example,
HSPB5 was shown to prevent thermal unfolding and aggregation
of myosin II, which allows maintenance of myosin enzymatic prop-
erties and thereby muscle contractile activity [102].
3. sHSPs in cardiac muscle
3.1. Cardiogenesis
Formation of the heart starts during gastrulation, when heart
mesoderm is speciﬁed. Highly regulated migration of these precur-
sors toward more anterior regions within the embryo occurs dur-
ing neurulation. As development proceeds, cardiac precursors
undergo a second migration event which comprises ventral move-
ment toward the anterior ventral midline, where formation of the
heart tube (connected with fusion and proliferation processes) oc-
curs [103–106].
Early expression of some sHSPs (especially orthologues of
HSPB1, HSPB8, HSPB5, but also HSPB6 and HSPB2) during heart for-
mation has been reported in a wide range of animal species such as
D. melanogaster [107], sea squirt [108], zebraﬁsh [10,90], mouse
[109], pig [110] and human [111,112]. In D. melanogaster, embry-
onic heart, which forms a contractile tube, is built of 104 cardiac
cells in which expression of two sHSPs (Hsp22 and Hsp26) was
conﬁrmed. Therefore a signiﬁcant role of these proteins in cardio-
genesis was postulated. This phenomenon has been investigated in
different animal models including zebraﬁsh [88] and Xenopus laevis
[113]. The expression pattern of HSPB1 is very similar in X. laevis
and zebraﬁsh [114,115]. In both cases its production starts in the
whole embryo during the gastrulation stage; as development pro-
ceeds it is initially restricted to somites, and then expands to the
entire myotome, as well as jaw and body wall muscles and heart
during the tadpole stage.
In X. laevis involvement of HSPB1 in cardiogenesis has been
proven. The role of this protein is connected with the fusion of
cardiac progenitors. The presence of HSPB1 enables proper heart
development, whereas its depletion leads to cardiac malforma-
tion manifesting as cardia biﬁda (characterized by the presence
of two unfused or partially fused contractile hearts) [113]. At
the subcellular level lack of HSPB1 results in perturbation of
the actin ﬁlament network and myoﬁbril disorganization.
Although involvement of this protein in functional heart forma-
tion is conﬁrmed, its lack does not affect cardiac differentiation.
In the light of these data it seems plausible that HSPB1 involve-
ment in cardiogenesis is connected with cell motility and/or
adhesion [113]. However, there is some discrepancy between
functions of this chaperone in X. laevis and other systems: D. rerio
and D. melanogaster. Data obtained from these two model organ-
isms led to the conclusion that HSPB1 is dispensable for morpho-
genesis but is involved in the maintenance of muscle integrity
and in the stress response (see Section 2.1: ‘‘Myogenesis’’). In
zebraﬁsh its orthologue could play a role in long-term mainte-
nance of heart and muscle tissues or, as in D. melanogaster, could
act as a chaperone involved in protection against starvation-in-
duced stress [88,116].
3.2. Cytoskeleton dynamics
Protection of cell function during stress is connected with the
ability of sHSPs to interact with cytoskeletal elements [117]. For in-
stance, HSPB1 interacts with muscle-speciﬁc structural proteins
and protects them, particularly in response to different stress
agents or injury mechanisms including heat shock [118], dilatedcardiomyopathy [111] prolonged exercise [100,101] and I/R (ische-
mia/reperfusion) injury [119].
With regard to the maintenance of cytoskeleton integrity,
which is necessary for cell survival, HSPB5 seems to be crucial, as
was indicated in in vitro and in vivo studies. It has been shown that
HSPB5 stabilizes not only IFs but also actin ﬁlaments as well as the
myoﬁbrillar protein titin. Interactions of HSPB5 with cytoskeletal
elements occur under both normal and stress conditions. Detailed
analysis revealed that the binding afﬁnity of HSPB5 to those pro-
teins increases after heat shock. Experiments on rat cardiomyo-
blasts have indicated that HSPB5 binds directly to actin ﬁlaments
and prevents their heat-induced as well as cytochalasin B-induced
disorganization. Furthermore, because this association was abol-
ished in the presence of MAPK inhibitors, it can be concluded that
it depends on the HSPB5 phosphorylation state [48,120,121]. These
mutual dependencies may be a result of a cascade in which a stres-
sor induces disruption of the cytoskeleton, which activates p38
MAPK and in turn leads to HSPB5 phosphorylation, which then
triggers its protective function towards the cytoskeleton [122].
With regard to the polymerization-interfering agents, similar ef-
fects were obtained for nocodazole-induced microtubule disas-
sembly, which was inhibited in the presence of HSPB5 [123].
Other agents, such as oxidative stress, which have an effect on
heart cells, also involve HSPB5 action. For example, translocation
of the cytosolic fraction of HSPB5 to the Z-disk was observed in car-
diac tissue as a result of ischemia, which suggests that HSPB5 takes
part in myocardium protection [124].
HSPB1 is associated with Z-disk maintenance. Localization of
HSPB1 in resting length myoﬁbrils correlates with regions adjacent
to the Z-line, which may suggest its interaction with proteins that
are components of this structure. However, analysis of HSPB1 dis-
tribution in stretched myoﬁbrils reveals that its localization does
not depend on desmin, a-actinin, myosin, or ﬁlamentous actin,
but is connected with titin ﬁlaments [90]. It is postulated that
interaction of HSPB1 with titin, a protein critical to the mainte-
nance of myoﬁbril structure, or titin-associated proteins such as
DRAL/FHL2 (down-regulated in rhabdomyosarcoma LIM domain
protein/four-and-a-half-LIM domain protein 2), cardiac ankyrin re-
peat protein, and ubiquitously expressed calpain may play a crucial
role in its muscle protection activity [90]. The putative interaction
between HSPB1 and calpain could prevent overactivation of cal-
pain proteolytic activity, which is a consequence of a massive cal-
cium inﬂux that occurs after muscle injury [90,125]. This putative
interaction could also shed some light on theantiapoptotic proper-
ties of HSPB1, since participation of calpain in necrosis and apopto-
sis in various cell types has been proven [126].
A phenomenon strictly associated with heart functioning in
which cytoskeletal rearrangement takes place is tachycardia
remodeling (TR). TR is an event preceding atrial ﬁbrillation in
which a pivotal role is played by RhoA GTPase (Ras homolog gene
family, member A), a small protein that regulates the actin cyto-
skeleton in the formation of stress ﬁbers. At the cellular level
tachycardia remodeling is connected with electrical, structural
and contractility changes of the atrial myocytes as a consequence
of RhoA GTPase activation [127]. It is postulated that members of
the sHSP family such as HSPB1, HSPB6, HSPB7 and HSPB8 are able
to modulate RhoA GTPase functioning and thereby tachycardia
remodeling [128]. Their activity has a protective effect and pre-
vents formation of F-actin stress ﬁbers, although the way of action
differs between sHSP family members. HSPB1, HSPB6 and HSPB7
directly prevent stress ﬁber formation, whereas HSPB8 action is
indirect via inhibition of RhoA GTPase [128]. It is suggested that
the unique ability of HSPB8 to inhibit stress ﬁber formation may
be connected with its function in autophagy activation, which in
turn acts as a trigger in RhoA pathway initiation [29,128].
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The most abundant organelles in cardiomyocytes are mitochon-
dria, which is the consequence of the high energetic demand of
these contractile cells. The numerous mitochondria contribute to
formation of signiﬁcant amounts of ROS, which are capable of dis-
turbing inter alia myoﬁbrillar proteins. That implies the necessity
for maintenance of redox balance in cardiomyocyte, a process in
which sHSPs take part [129]. Participation of sHSPs in maintaining
redox homeostasis is mostly connected with modulation of GSH le-
vel and increase of its expression level.
The expression of mammalian HSPB1 is augmented during
postnatal development, which is probably connected with the in-
crease of cardiac activity that generates ROS-induced oxidative
stress [112]. Elevated levels of HSPB1 and HSPB5 were observed
in hearts of mice and rats aged from 3 to 6 months [130,131] and
in hearts of PIT1-deﬁcient mice, whose lifespan is extended in
comparison to wild type mice [132]. This result may suggest
involvement of sHSPs in proper function of this contractile organ.
Engagement of HSPB1 and HSPB5 in cytoprotection against oxi-
dative stress is connected with their ability to intensify the activity
of enzymes such as glucose 6-phosphate dehydrogenase (G6PD),
responsible for regulation of GSH level, which is known to protect
cells from I/R-induced damage [133]. This is in agreement with
experiments on depletion of heat shock transcription factor 1
(HSF1) in cardiac cells, which leads to downregulation of HSPB1
and HSPB5 and reduction of G6PD activity [134]. Conversely, high
overexpression of HSPB1 in heart results in elevation of GSH level
and in reduction of ROS production [135]. However, HSPB1 deple-
tion does not cause expected effects such as changes in GSH and
mRNA levels for several relevant sHSPs [85].
At least two sHSP family members – HSPB1 and HSPB5 – are
implicated in reductive stress, which is underlain by impairment
of the activity of enzymes implicated in the production and recy-
cling of GSH. There is evidence that HSPB1 in cells plays a role as
an antioxidant. An increased level of HSPB1 causes reductive stress,
which leads to cardiac hypertrophy and cardiomyopathy. In
cardiomyocytes reductive stress-induced disturbances are mani-
fested by an increased ratio of reduced GSH/oxidized GSH and a de-
creased level of ROS, and are connected with upregulation of
glutathione peroxidase 1 [135], while HSBP5 in its mutant form
(R120G) contributes to the development of a multisystem protein
aggregation disease with cardiomyopathy syndrome. This is also
a consequence of reductive stress in the myocardium, in which
an increased ratio of reduced GSH/oxidized GSH as well as mutant
protein aggregation was observed. This disruption is strictly re-
lated to intensiﬁcation of G6PD, glutathione reductase, and gluta-
thione peroxidase expression [130].
Two pathological phenomena closely connected with redox
imbalance are myocardium ischemia and reperfusion (I/R). These
processes are closely interrelated. Ischemia is induced by an insuf-
ﬁcient supply of blood to the heart, which obstructs delivery of
oxygen and nutrients. Reperfusion in turn is the consequence of
the restoration of blood ﬂow to cardiac cells that have previously
experienced deﬁcient blood circulation. In the presence of an
excessive amount of oxygen cardiomyocytes are exposed to in-
creased ROS production, which may lead to oxidative stress-induc-
ible tissue damage and can induce necrosis or apoptosis. sHSPs
seem to be the ﬁrst line of defense against I/R insult. Many differ-
ent studies have proven that their overexpression protects the cell
against I/R damage, as was conﬁrmed for HSPB1, HSPB5, HSPB6
and HSPB8 [136–140]. The increased level of both HSPB1 and
HSPB5 guards adult cardiomyocytes against ischemic injury. More-
over, HSPB5, in contrast to HSPB1, has a similar effect on neonatal
cardiac cells subjected to simulated ischemic stress [136]. These
data indicate that outcomes of I/R insult as well as protectiveabilities of different sHSPs are dependent on the age of the organ-
ism. The protective effects of sHSPs against I/R injury depend on
their posttranslational modiﬁcations, such as phosphorylation.
For instance, cardioprotective activity of overexpressed HSPB1 is
even more effective when accompanied by mutations of serine res-
idues that prevents its phosphorylation [137] whereas overexpres-
sion of HSPB6 without a speciﬁc phosphorylation site (S16) has a
dramatic opposite effect [138]. Involvement of HSPB6 in cardiopro-
tective mechanisms seems to be bipolar. On the one hand, HSPB6
attenuates cell death by interacting with Bax and thereby increas-
ing the Bcl2/Bax ratio. On the other hand, inhibition of HSPB6
phosphorylation (S16) contributes to increased cell mortality by
activation of stress-induced autophagy [141]. The signiﬁcance of
serine 16 in the cardioprotective activity of HSPB6 has been con-
ﬁrmed by identiﬁcation of a mutation (P20L substitution) in its hu-
man ortholog that causes reduction of S16 phosphorylation, which
in turn leads to abolition of the ability of this chaperone to protect
cells against stress [142]. Overexpression of HSPB6 in the heart
does not inﬂuence cardiac morphology but has an impact on its
contractile function, which it intensiﬁes due to inhibition of type
1 protein phosphatase (PP1), thereby maintaining phospholamban
(PBN), an inhibitor of cardiac muscle sarcoplasmic reticulum Ca2+-
ATPase (SERCA), in the phosphorylated state. The phosphorylated
PBN is not able to fulﬁll its inhibitory function, thereby allowing
muscle contraction [143].
Changes in myocardial distribution of different sHSPs were ob-
served shortly after ischemic stress exposure. [144,145]. Five of the
sHSPs – HSPB5, HSPB2, HSPB1, HSPB6 and HSPB7 – relocate from
the cytoplasm to the Z and/or I line regions of myoﬁbrils, which
may be stabilized by them. The translocation may also protect pro-
tein components of Z and/or I lines from unfolding or aggregation
during stress conditions. HSPB2 and HSPB6 bind to actin-associ-
ated proteins, whereas HSPB5 interacts mainly with titin and des-
min [146]. In ischemic cardiac cells HSPB5 is located at the Z lines
present within the I line, whereas in skeletal muscles this protein is
distributed throughout the entire I band. Experiments carried out
on HSPB5/HSPB2-deﬁcient hearts show an increased I/R insult with
a less efﬁcient recovery after ischemia [92,145]. These studies sug-
gest involvement of these two sHSPs in maintaining cardiac muscle
elasticity, functional recovery and protection from I/R-induced
necrosis and apoptosis. Their role in the contraction process may
be excluded, since the morphological and functional properties of
HSPB5/HSPB2 deﬁcient hearts were similar to WT hearts under
non-stressful conditions [92,145]. Moreover, double knockout
cardiomyocytes exhibit increased mitochondrial permeability
transition andmitochondrial calcium uptake [147], and reduced le-
vel of GSH after ischemic stress [92]. However, since other
researchers obtained contradictory data on the signiﬁcance of
these two sHSPs for recovery after I/R stress, this issue needs fur-
ther investigation [148].
Ischemic stress induces translocation of sHSPs in cardiac cells
not only to myoﬁbrillar structures but also to other cellular compo-
nents such as mitochondria. This concerns HSPB2 [149] and HSPB5
[150]. Association of HSPB5 with the outer mitochondrial mem-
brane depends on its phosphorylation via p38 MAP, and contrib-
utes to modulation of mitochondrial damage upon reperfusion
[150]. Other studies have brought further information about the
distinct roles of HSPB5 and HSPB2 in cardiac cells. The ﬁrst one
seems to be responsible for diastolic performance and structural
stability, the second for systolic performance and cardiac energet-
ics [151].
Ischemic stress leads to upregulation of HSPB8 expression
[139,152]. Experiments carried out on transgenic mice with specif-
ically upregulated HSPB8 levels have indicated that HSPB8 is in-
volved in cardioprotection via a nitric oxide (NO)-dependent
mechanism in the context of ischemia [153]. Protective activity
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volves activation of cell survival pathways, upregulation of heat
shock proteins, inhibition of apoptosis, and metabolic adaptation
[71,140]. The upregulation of HSPB8 is correlated with increased
expression of the inducible isoform of nitric oxide synthase (iNOS)
[140,153]. iNOS plays a role in NO-mediated adaptation in mito-
chondrial respiratory function, by reduction of ROS production
via interaction with components of the electron transport chain.
iNOS participation in mitochondrial activity inhibits proapoptotic
events [154,155].
Some members of the sHSP family are also involved in the re-
sponse to the oxidative stress that is an effect of anticancer drug
treatment. For example, oxidative stress effects manifested by
the increase of phosphorylated HSPB1 level were induced in mouse
heart by chemotherapeutic drugs such as doxorubicin [156]. Accu-
mulation of HSPB1 in the responses to drug-induced oxidative
stress depends on HSF1 and leads to the loss of cardiomyocytes
via activation of the proapoptotic protein Bax. Accumulation of an-
other sHSP – HSPB6 – in mouse cardiomyocytes was also observed
in the response of doxorubicin-induced oxidative stress [157].
3.4. HSPBs during cardiac hypertrophy
Cardiac hypertrophy is an abnormal enlargement of the heart
muscle associated with an increased cardiomyocyte volume in re-
sponse to pressure and volume overload. Cardiac hypertrophy may
occur as a consequence of overexpression of some sHSPs such as
HSPB1 [158], HSPB6 [159] and HSPB8 [152]. Mechanisms underly-
ing the cardiac hypertrophy are linked to regulation of the post-
translational modiﬁcation of sHSP. This was recently conﬁrmed
in the case of HSPB6, whose protective abilities depend on its phos-
phorylation on Ser16 by PKA (protein kinase A). Phosphorylation of
HSPB6 is inhibited by its direct interaction with cAMP phosphodi-
esterase-4 (PDE4). Attenuation of HSPB6 phosphorylation by PKA
due to b-adrenergic stimulation is achieved by inhibition of its
binding to PDE4. Phosphorylated HSPB6 protects against cardiac
hypertrophy [159].
HSPB8 was also found in hypertrophic heart. Increase of its level
in hearts of transgenic mice leads to cardiac hypertrophy propor-
tionally to the level of its overexpression. An elevated level of
HSPB8 stimulates the AKT pathway [152]. Depletion of HSPB8 in
mice does not cause any signiﬁcant changes in embryos developing
under normal conditions and does not inﬂuence their viability
[160]. Moreover, mitochondrial activity seems not to be affected
by depletion or overexpression of HSPB8 in the absence of stressful
agents [160]. However, HSPB8-knockout mice under stress condi-
tions such as pressure overload show different abnormalities
including hypertrophy, ventricular dilation, impaired contractile
function, increased cardiomyocyte length and accumulation of
interstitial collagen, faster transition into heart failure, and in-
creased mortality. The conducted study suggests HSPB8 involve-
ment in the mechanism of cardiac response to overload via
modulation of nuclear and mitochondrial STAT3 (Signal transducer
and activator of transcription 3) activity. STAT3 is a stress-induc-
ible transcription factor responsible for cardiac cell survival [160].
The induction of myocardial hypertrophy depends on mechano-
transduction involving integrins – proteins that mediate interac-
tions with the external milieu and are reputed to be receptors of
mechanical stress [161]. Integrin-mediated signal transduction in-
volves the phosphorylation signaling cascade in which different
proteins such as Focal adhesion kinase (FAK), c-Src tyrosine kinase,
growth factor receptor-bound protein 2 (Grb2) and Son of Seven-
less (SOS) take part [162]. This signaling induces the Ras/ERK path-
way responsible inter alia for growth regulation. At least some of
these proteins such as c-Src regulate myocardial hypertrophic
growth by their association with cytoskeletal structures [162].Another signaling protein that promotes cardiac hypertrophy is
p38 mitogen-activated protein kinase (MAPK) [163]. p38 MAPK is
also responsible for modulation of HSPB1 function such as regula-
tion of the organization of the actin cytoskeleton under stress con-
ditions [117,164]. Due to the ability to modulate the dynamics of
the actin cytoskeleton, phosphorylated HSPB1 can play a role in
plasma membrane-associated signal transduction. Moreover, as a
result of activation of p38 MAPK, the phosphorylated HSPB1 is
translocated from the cytosol to the Z-disks of myoﬁlaments,
where it takes part in protection of structural proteins such as des-
min [165].
Integrin signaling, p38 MAPK, HSPB1 and cytoskeleton are in-
volved in the hypertrophic growth induced by mechanical stress,
e.g. stretch [161]. The opposite effect, i.e. atrophy, also requires
engagement of the integrin pathway, HSPB1 and its upstream reg-
ulator p38 MAPK. Cardiac atrophy, which is a manifestation of
adaptation to reduced myocardial load and work, occurs in re-
sponse to different stress agents such as microgravity induced by
hindlimb unloading [166,167].4. sHSPs in smooth muscle
4.1. Functions of sHSPs in smooth muscles
The sHSPs HSPB1, HSPB6 and HSPB5 are chaperone proteins
intensively expressed in smooth muscles. They play a signiﬁcant
role in themodulation of muscle contraction, cell migration and cell
survival [168]. They have been found in arterial [169], airway [170],
venous [171], bladder anduterine [172,173] smoothmuscles.Asdis-
cussed above, numerous cellular processes can be regulated by
sHSPs among which binding of misfolded proteins, maintenance of
cellular redox balance and actin polymerization should be men-
tioned. These processes inﬂuence smooth muscle proliferation, cell
migration, cell survival, muscle contraction and synthesis of signal-
ing proteins. A better understanding of sHSP functions may allow
one to explainmechanisms of smoothmuscle pathologies and elab-
orate appropriate medical treatment focused on sHSPs as potential
markers or drug targets. For example, the secreted HSPB1 could be
a useful marker of inﬂammation during atherogenesis. The phos-
phorylation of HSPB6, which relaxes smooth muscle, might prove
to be highly relevant to treatment of hypertension, vasospasm, asth-
ma, premature labor and overactive bladder. The phosphorylated
form of HSPB6 is implicated in smooth muscle relaxation and is
one of themost important phosphoproteins involved in this process
[174]. Because sHSPs can also modulate smooth muscle prolifera-
tion and cell migration, they may be targets for increasing effective,
novel treatments of clinical problems arising from remodeling of
smooth muscle in vascular, respiratory and urogenital systems.
Numerous studies have indicated that the expression of sHSPs
is very varied and depends on the type of smooth muscle and their
location. HSPB1 expression is very dynamic and can increase in re-
sponse to physical and chemical stressors including heat, mechan-
ical stress, oxidative stress and proinﬂammatory mediators [175–
177]. Similarly, HSPB6 expression in smooth muscles is also vari-
able and depends on various conditions [178]. For example, in
some vascular tissues, airway smooth muscle, and uterine smooth
muscles HSPB6 is expressed constitutively [169,178,179], whereas
in other tissues the expression of HSPB6 is at a low level [172].
4.2. HSPB1 in smooth muscle contraction
HSPB1 is a signiﬁcant protein involved in smooth muscle
contraction and migration [180]. It is commonly known that cell
proliferation depends on actin ﬁlament remodeling. Moreover,
cell survival is closely dependent on the integrity of the actin
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in the regulation of cytoskeletal dynamics, chieﬂy cell cytoskeletal
microﬁlaments. The examination of the involvement of HSPB1 in
smooth muscle contraction has indicated that this process is
dependent on MAP kinases and is closely connected to phosphory-
lation of the smooth muscle protein caldesmon. Caldesmon is
responsible for the regulation of smooth muscle as well as non-
muscle contraction, and is a substrate for ERK and p38MAP kinases
[181,182]. This protein, in cooperation with HSPB1 among others,
is able to modulate actin–myosin interaction and thereby inﬂu-
ences muscle contraction. After phosphorylation both proteins
form a complex in which phosphocaldesmon undergoes conforma-
tional change resulting in its dissociation from tropomyosin. This
leads to the sliding of tropomyosin on actin and eventually to
smooth muscle contraction [182].
Actin is particularly responsible for the maintenance of cell
shape. This function depends on actin polymerization, which must
be orchestrated both temporally and spatially [183]. Several stud-
ies have shown that overexpression of HSPB1 increases the stabil-
ity of actin microﬁlaments during exposure to different stress
agents such as hyperthermia, redox status and cytochalasin D
[184]. Under stress conditions, the integrity of F-actin is disrupted
by uncontrolled rupture and aggregation of ﬁlaments, which
demolishes cell morphology. It is suggested that HSPB1 interacts
with F-actin during heat stress. This interaction may be an adaptive
response to changes in the cellular environment, in order to stabi-
lize the structure and prevent cytoskeleton disaggregation also in
smooth muscle cells. The exact mechanism by which HSPB1 stabi-
lizes F-actin is poorly understood.
An interaction of HSPB1 and HSPB5 with various IFs has also
been reported [34]. It is proposed that these interactions could in-
volve the connections between ﬁlaments in cellular networks, an
event that might be important for the survival of cells. Evidence
also suggests that HSPB1 co- localizes with tubulin/microtubules,
although the signiﬁcance of this observation is not fully under-
stood [185].
4.3. HSPB1 in cell migration
Smooth muscles are exposed to numerous growth factors and
proinﬂammatory cytokines that lead to abnormalities such as ath-
erosclerosis, angiogenesis, and smooth muscle hypertrophy. Cell
migration is another function that depends mainly on the conver-
sion of G-actin to F-actin in smooth muscles. The common feature
of these pathological changes is the migration of smooth muscle
cells. The extracellular signaling pathways activating migration of
smooth muscle are often not fully understood. Hedges et al.
[186] studied migration of cultured myocytes from the trachea in
response to platelet-derived growth factor, interleukin-1 beta
and transforming growth factor-beta. They blocked the migration
of cells by the use of SB203580 (pyridinyl imidazole) which is an
inhibitor of p38 MAPK. They observed during the course of these
experiments prolonged phosphorylation of the kinase. Activation
of this kinase induced phosphorylation of HSPB1, which could
inﬂuence the polymerization of F-actin. They used adenovirus-
mediated expression of activated mutant MAPK kinase 6b(E), an
upstream activator for p38 MAPK, which increased cell migration.
However, overexpression of p38alpha MAPK dominant negative
mutant and an HSPB1 phosphorylation mutant blocked cell migra-
tion completely. The results showed that activation of the p38
MAPK pathway by growth factors and proinﬂammatory cytokines
regulates smooth muscle cell migration and might lead to patho-
logical states involving smooth muscle dysfunction [186,187]. Lan-
dry and Hout [117] examined the migration of vascular endothelial
cells, and discovered that vascular endothelial migration dependson p38 MAP kinase [188]. In response to activation by serum
growth factors and cytokines, p38 MAPK phosphorylates partici-
pants of the signaling pathway mediated by HSPB1 [189,170]. Sub-
sequent examination by other groups conﬁrmed that the p38
pathway MAPK/MK2/HSPB1 is necessary for the migration of vas-
cular smooth muscle cells [190], neutrophils [191], ﬁbroblasts
[192] and mammary epithelial cells [193]. Other studies have pro-
ven that motility of the intracellular pathogen Listeria monocytoge-
nes is based on intracellular actin polymerization and may be
inhibited by suppression of HSPB1 phosphorylation. The results
indicate that activation of the p38 MAPK pathway by growth fac-
tors and proinﬂammatory cytokines regulates smooth muscle cell
migration and may be implicated in pathological states involving
smooth muscle dysfunction [42,194].
4.4. Functions of HSPB6 in smooth muscle
The increase of myoplasmic Ca2+ induces smooth muscle con-
traction via the activation of myosin light chain kinase (MLCK)
and phosphorylation of myosin regulatory light chains (MRLC)
[195]. The phosphorylation of MRLC on Ser19 permits actin and
myosin interaction, which leads to generation of smooth muscle
contraction [196]. HSPB6 plays an opposite role compared to
HSPB1 in smooth muscle contraction. The investigation showed
that phosphorylated HSPB6 is a signiﬁcant inhibitor of smooth
muscle contraction [196,197]. There are two possible models of
this mechanism: cyclic nucleotide dependent (PKA/PKG) depoly-
merization of F-actin or a direct inhibitory outcome on actomyosin.
One of the more important features of HSPB6 in smooth muscle
physiology is the phosphorylation of Ser16 by one of the kinases
PKA/PKG. The increase in phosphorylation is induced by enlarging
the vessel, which has been connected with HSPB6 aggregation in
the carotid artery of smooth muscle [179,198]. It is commonly
known that cyclic nucleotide-independent relaxation is the main
effect of reducing the intracellular level of calcium and dephospho-
rylation of myosin light chains. However, other studies of smooth
muscle relaxation reveal a pathway independent of changes in
phosphorylation of myosin light chain [180,199]. The phosphoryla-
tion of HSPB1 inhibits HSPB6 phosphorylation and is associated
with reduced cyclic nucleotide-dependent vascular smooth muscle
relaxation [176].
HSPB6 can also react with 14-3-3 proteins, which bind phos-
phoproteins. HSPB6 can decrease phosphorylation of coﬁlin – an
actin-binding protein engaged in its disassembly – and disrupt ac-
tin in smooth muscle, suggesting that one possible mechanism by
which HSPB6 mediates smooth muscle relaxation is by regulation
of actin ﬁlament dynamics [3,38,200–203]. This is in agreement
with the fact that the inhibition of actin polymerization is sufﬁ-
cient to relax smooth muscle, although it is not required [204].
Phosphorylated HSPB6 is a functional smooth muscle relaxant
and can be applied to develop new vasodilators and
bronchodilators.
5. Pathological aspects of sHSPs
The higher order organization of sHSPs is based on the forma-
tion of dynamic oligomers in which subunits undergo exchange.
Due to this property sHSPs are able to participate in the retention
of cell proteostasis by protecting structure and function of various
proteins and thereby prevent different diseases. When sHSPs are
perturbed (e.g. by mutation of the cognate genes) their presence
may contribute to the disruption of some cellular activities and
to the development of disease phenotypes.
Among genes coding for sHSPs, CRYAB undergoes the most
frequently genetic alternation that may lead to diverse and
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consequence of participation of this multifunctional protein in
various cellular processes. Besides HSPB5, other sHSP family
members prone to mutations of their genes should be mentioned,
i.e. HSPB1, HSPB6 and HSPB7. Mutations affecting HSPB5 inﬂuence
its intramolecular (e.g. D109H) [205] as well as intermolecular
interactions (e.g. R120G) [35,206].
Among disorders in which sHSPs are implicated, desmin-related
myopathy (DRM) is one of the best known. It is caused by several
mutations in the CRYAB gene, including R120G (also connected
with cataract); DC13 (464delCT), DC15 (450delA), and Q151X
mainly affecting both muscular and cardiac tissues [44,207–210].
The arginine residue at position 120 in the ACD is highly con-
served and has been shown to be essential for the solubilization
and chaperone activity of HSPB5 [44,207]. The functional signiﬁ-
cance of this residue can be illustrated by the fact that it is present
in vertebrates (mouse, zebraﬁsh) as well as in invertebrates (e.g. D.
melanogaster). Mutation of this residue that leads to DRM that is
inherited in an autosomal-dominant manner and causes a loss of
the chaperone activity of HSPB5 in vitro, and is expected to pro-
mote interaction between the mutant protein and the type III IFs.
It has been reported that the R120G mutation enhances the bind-
ing capacity of HSPB5 for desmin and decreases its dissociation
constant [43]. Biochemical and structural studies have revealed
that the R120G mutation in HSPB5 disrupts protein secondary, ter-
tiary and quaternary structure. Muscle cell lines transfected with
the mutant cDNA encoding HSPB5 showed intracellular aggregates
that contain both desmin and HSPB5, which are similar to spheroid
inclusion bodies found in DRM patients. In non-pathological condi-
tions a small amount of abnormal desmin interacted with HSPB5,
remained soluble, and subsequently degraded. As a consequence
of CRYAB mutation, misfolded desmin forms aberrant aggregates
and disrupts the integrity of the sarcomere network, thus giving
rises to pathological consequences in muscle ﬁbers [211]. It has
been suggested that desmin aggregates observed in DRM patients
may not be due to direct physical or biochemical interaction be-
tween desmin and mutant HSPB5, but rather due to loss of HSPB5
‘‘chaperoning’’ function [43]. In a knock-in mouse model for R120G
mutation of HSPB5 both heterozygous and homozygous mutant
mice developed myopathy similar to that in humans carrying the
HSPB5 R120G mutation, with insoluble aggregates containing
abnormal HSPB5 and desmin [212]. However, how mutated HSPB5
contributes to these pathological states is still not clearly under-
stood. According to some theories, formation of aggregates super-
vised by, inter alia, sHSPs may be a kind of protective mechanism
by which organisms eliminate potentially toxic polypeptides
whose soluble forms could affect cells in a much more severe man-
ner [213]. Formation of aggregates may also arise through the
overloading of a protective mechanism which is no longer able to
efﬁciently eliminate undesirable peptides [214].
Recently, also recessively inherited, a more severe form of
HSPB5-related myoﬁbrillar myopathy (MFM) has been identiﬁed.
The more severe phenotype is probably a result of homozygosity
for the mutation (c.343delT). Infant patients affected with disease
caused by the relevant mutation show, besides symptoms charac-
teristic of other forms of DRM, also profound muscle stiffness,
which may suggest involvement of the CRYAB gene product in
modulation of muscle contractility. According to the postulated
explanation, abnormal muscle activity may be connected with dis-
ruption of the HSPB5 translocation process to the Z-disk during
muscle contraction, which may disturb the mechanism responsible
for the maintenance and repair of contractile units [215].
Mutation R120G in the CRYAB gene has also been linked with
cardiomyopathy. At the molecular level the presence of mutant
protein in cardiomyocytes leads to abnormalities in HSPB5 as well
as desmin aggregation [209]. It is also associated with reductivestress. In mice overexpression of HSPB5R120G leads to the develop-
ment of desmin-related cardiomyopathy, which is demonstrated at
the molecular level by formation of aggresomes including HSPB5
and desmin, and myoﬁbrillar disorganization [130,209]. Other
sHSPs can also be responsible for the development of cardiomyo-
pathic phenotype. For example, HSPB8 is implicated in idiopathic
dilated cardiomyopathy [216–218].
An accumulation of misfolded proteins induces proteotoxic
stress and invokes in the cell a stress response connected with ele-
vation in the expression levels of different HSPs, including HspB1,
HspB5, HspA1–Hsp70 and Hsp90 alpha [130,219]. Attenuation of
HSP expression contributes to restoration of redox balance; how-
ever, the presence of mutant protein shifts the equilibrium toward
reductive stress.
The presence of aggregates formed due to the presence of mu-
tated HSPB5 is accompanied by high oxidative stress. This occurs
via the Nrf2 pathway [220]. The presence of toxic complexes has
additional effects such as sequestration of different proteins crucial
for protein homeostasis maintenance, including HSPB1, KEAP1 (a
negative regulator of Nrf2) and G6PD. It also leads to the disruption
of cardiac sarcomeric units [221].
Furthermore, mutations in binding partners of sHSPs may also
affect functions of this chaperone leading to the development of
pathological phenotypes similar to those deriving from abnormal-
ities in genes coding for sHSPs. For example, mutation (P209L) of
BAG3 in the region responsible for binding HSPB8 and HSPB6 re-
sults in childhood muscular dystrophy with progressive limb and
axial muscle weakness. Affected patients develop cardiomyopathy
and peripheral neuropathy symptoms [222,223].
Altered expression of some sHSPs was observed in different car-
diac pathologies, e.g. HSPB1 level is changed in patients with con-
gestive heart failure [224]. Acute ischemia also causes upregulation
of HSPB1 expression in myocardial tissue [225], which is connected
with its role in cardiac muscle protection from different stressors
[136]. Distribution of HSPB1 is also changed in some pathological
states such as cardioplegia, in which HSPB1 is translocated to the
myoﬁlaments [226].
In the case of muscle activity, the protein quality control system
supervises the fate of sarcomeric components on several levels,
which include: correct folding of newly synthesized proteins, their
incorporation into existing ﬁlaments, disks or other structures, ex-
change of individual elements without affecting the functioning of
the others, and with the maintenance of entire muscle integrity. As
members of the PQC system sHSPs participate in all these pro-
cesses in a direct or indirect manner. However, their main goal
seems to be protection of muscle components from unfavorable
changes that are consequences of activity of different stress agents.
Thereby the necessity of understanding functioning of sHSPs both
under normal and pathological conditions seems to be reasonable.
Furthermore, a better understanding of this issue should allow sci-
entists to elaborate effective medical tools for treatment of patho-
logical states connected with disrupted chaperones.6. Perspectives
The multifunctional character of sHSPs leads to their involve-
ment in a variety of cellular processes. In normal conditions they
act as housekeeping proteins, whereas in stress conditions they
help maintain or restore cell homeostasis. In pathological states,
such as cancer and ischemia, their multifunctional nature seems
to present a serious obstacle hindering their potential usage in
medical treatment of different pathological states. A successful
and tissue-speciﬁc treatment demands accurate drug administra-
tion in a way that allows minimizing side effects (e.g. in cancer
therapy an effect on cardiac function due to the increased level
526 M. Dubin´ska-Magiera et al. / FEBS Letters 588 (2014) 517–530of oxidative stress). This in turn creates an urgent need for further
investigation of the properties of sHSPs, their binding partners (i.a.
ATP-dependent chaperones and their co-chaperones), analysis of
the signaling pathways modulated by them, and interactions of
genes encoding them with different transcription factors that act
in a stage- and tissue-dependent manner. Additionally, since the
chaperone activity of sHSPs is regulated by post-translational mod-
iﬁcations such as phosphorylation (whose impairment contributes
to various pathological conditions including cancer), these modu-
lating functions require a detailed elucidation. Moreover, one of
unanswered question regarding these proteins is: which functions
of different sHSPs overlap and which are distinct in the developing
and adult tissues (including all three types of muscle) in normal as
well as pathological conditions? Solution of these issues would al-
low us to decipher mechanisms of action of sHSPs in various tis-
sues and in the whole organism. Besides expansion of the basic
knowledge about sHSPs, this might also allow devising a tissue-
speciﬁc delivery technique for the existing sHSP-based therapeutic
agents as well as the development of new competitive sHSP inhib-
itors which meet the challenges of contemporary medicine.
As mentioned above, one of the current directions in sHSP re-
search is focused on examination of their usage as target proteins
in medical approaches. For example, in the case of muscle regener-
ative medicine, application of HSPB6 has given promising results
[227]. Injection of mesenchymal cells overexpressing this protein
in ischemic hearts improved survival of cardiomyocytes. This is
due to the ability of overexpressed HSPB6 to activate the Akt path-
way-dependent secretion of growth factors such as VEGF, FGF2 and
IGF1 [227]. Controlled overexpression of HSPB1 via pharmacologi-
cal inducers such as Herbimycin A and Geranylgeranylacetone
(GGA) in tissues prone to ischemic damage also seems to be a rea-
sonable therapeutic approach to enhancing its cardioprotective
activity [228].
Also the pro-oncogenic role of some sHSPs, e.g. HSPB1 or HSPB8,
complements (but not exhausts) the long list of their activities and
is the subject of cancer research. Overexpression of these proteins
was conﬁrmed in different types of tumors (see chapter 1.2). Their
connections with tumorigenesis consists in involvement in the
development of drug resistance – a disadvantageous phenomenon
which is one of the most important reasons for low effectiveness of
chemotherapy. Elimination of sHSPs, in view of their cytoprotec-
tive properties (which leads to cancer cell chemosensitization
and radiosensitization), seems to be a reasonable strategy in the
battle against cancer. To achieve this purpose, a broad spectrum
of potential therapeutic agents is used. They include three distinct
classes of molecules: small molecule inhibitors, antisense oligonu-
cleotides, and protein aptamers. It is noteworthy that these novel
sHSP-based drugs have already found (or will ﬁnd in the nearest
future) application in therapies for other types of disease.
Finally, in chapter 1 we have emphasized the evolutionary con-
servation of sHSPs, which are synthesized in almost all organisms.
This makes it possible to compare the results of sHSP studies ob-
tained from different models (invertebrate as well as vertebrate).
Also the pathological implications of different sHSPs seem to be
evolutionarily conserved (e.g. the amino acid residue R120 of
HSPB5 altered in human DRM disease is conserved in other verte-
brates including mouse and zebraﬁsh, as well as in the invertebrate
D. melanogaster. Therefore, creation of human disease models using
mouse, ﬂy, zebraﬁsh, and other animals is justiﬁable and improves
our understanding of the etiology of pathological phenotypes.
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